GNLX shows severe financial deterioration with stockholders' equity collapsing 56% and current assets declining 52% while burning cash at an accelerated rate.
The company is experiencing a liquidity crisis with current assets falling from $31.5M to $15.1M and operating cash flow worsening to -$25.3M, indicating unsustainable burn rates. With cash declining to $5.3M and accelerating losses, GNLX faces potential going concern issues and may need immediate financing or strategic alternatives to continue operations.
GNLX exhibits across-the-board financial deterioration with stockholders' equity plummeting 56% to $11.5M and current assets halving to $15.1M, while total assets declined 45% to $19.0M. Operating cash flow worsened 19% to -$25.3M despite increased capital expenditures of $1.1M, and cash reserves fell 38% to just $5.3M. This financial profile suggests a biotech company burning through capital at an unsustainable pace with diminishing liquidity buffers, creating immediate financing pressures.
Capital expenditure jumped 188.2% — major investment cycle underway; assess returns on deployment.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current assets declined 52% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 45.2% — asset sales, write-downs, or balance sheet optimization underway.
Cash declined 37.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Liabilities reduced 11.4% — deleveraging improves balance sheet strength and financial flexibility.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →